Prurigo Nodularis Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Prurigo Nodularis Marketed and Pipeline Drugs Report Overview
Prurigo Nodularis (PN) is a chronic inflammatory skin disorder characterized by intensely itchy, pink-colored papules, plaques, and nodules that can be found on various parts of the body. PN is characterized by dysregulation of skin nerves and immune cells, resulting in reduced nerve fibers in the epidermis and increased fibers in the dermis, along with heightened inflammatory cytokines and immune cell activity.
| Key Mechanisms of Action (Marketed) | · Receptor Antagonist
· Enzyme Inhibitor · Receptor Agonist · Ion Channel Blocker |
| Key Molecule Types | · Small Molecules
· Biologic |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
The Prurigo Nodularis marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, and pricing and reimbursement of therapy in major countries. Furthermore, the report analyzes late-to-mid-stage pipeline products with Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA) for Prurigo Nodularis.
The report also provides actionable insights into the clinical and commercial landscapes of Prurigo Nodularisdrugs, M&A deals, and market catalysts. These critical data will help you develop and design your in-licensing and out-licensing strategies. Furthermore, identify companies with the most robust pipelines to create smart business goals.
| Key Mechanisms of Action (Pipeline) | · Receptor Antagonist
· Enzyme Inhibitor · Protein and Peptide Inhibitor · Receptor Agonist · Receptor Inhibitor |
| Key Molecule Types (Pipeline) | · Biologic
· Small Molecule |
| Top Sponsors (Marketed and Pipeline Drugs) | · Incyte Corp
· Sanofi · Galderma SA · Maruho Co Ltd · Amgen Inc |
| Enquire & Decide |
Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Prurigo Nodularis Marketed Drugs Market Segmentation by Mechanisms of Action
The key MoA of the marketed drugs for Prurigo Nodularis includes receptor antagonist, enzyme inhibitor, receptor agonist, and ion channel blocker among others. Most of the marketed drugs follow receptor antagonist MoA in 2024 in the Prurigo Nodularis market.
Prurigo Nodularis Marketed Drugs Market Analysis by Mechanisms of Action, 2024 (%)
Buy the Full Report to Know More about the MoA of Prurigo Nodularis Marketed Drugs
Prurigo Nodularis Marketed Drugs Market Segmentation by Molecule Types
In 2024, the leading molecule type for Prurigo Nodularis marketed drugs are small molecules and biologic.
Prurigo Nodularis Marketed Drugs Market Analysis by Molecule Types, 2024 (%)
Buy the Full Report to Know More about the Molecule Types of Prurigo Nodularis Marketed Drugs
Prurigo Nodularis Pipeline Drugs Market Segmentation by Mechanisms of Action
The key MoA of the drugs in the Prurigo Nodularis pipeline mainly includes receptor antagonist, enzyme inhibitor, protein and peptide inhibitor, receptor agonist, and receptor inhibitor. Most of the pipeline drugs for Prurigo Nodularis follow receptor antagonist MoA in 2024.
Prurigo Nodularis Pipeline Drugs Market Analysis by Mechanisms of Action, 2024 (%)
Buy the Full Report to Know More about the MoA of Prurigo Nodularis Pipeline Drugs
Prurigo Nodularis Pipeline Drugs Market Segmentation by Molecule Types
In 2024, the leading molecule type for Prurigo Nodularis pipeline drugs are biologic and small molecules.
Prurigo Nodularis Pipeline Drugs Market Analysis by Molecule Types, 2024 (%)
Buy the Full Report to Know More about the Molecule Types of Prurigo Nodularis Pipeline Drugs
Prurigo Nodularis Marketed and Pipeline Drugs Market – Competitive Landscape
A few of the top sponsors in the Prurigo Nodularis marketed and pipeline drugs market are Incyte Corp, Sanofi, Galderma SA, Maruho Co Ltd, and Amgen Inc among others. Incyte Corp is sponsoring the highest number of trials in 2024.
Prurigo Nodularis Marketed and Pipeline Drugs Market Analysis by Sponsors, 2024 (%)
Buy Full Report for More Sponsor Insights into the Prurigo Nodularis Marketed and Pipeline Drugs Market
Segments Covered in the Report
Prurigo Nodularis Marketed Drugs Mechanisms of Action Outlook (Number of Drugs, 2024)
- Receptor Antagonist
- Enzyme Inhibitor
- Receptor Agonist
- Ion Channel Blocker
Prurigo Nodularis Marketed Drugs Molecule Types Outlook (Number of Drugs, 2024)
- Small Molecules
- Biologic
Prurigo Nodularis Pipeline Drugs Mechanisms of Action Outlook (Number of Drugs, 2024)
- Receptor Antagonist
- Enzyme Inhibitor
- Protein and Peptide Inhibitor
- Receptor Agonist
- Receptor Inhibitor
Prurigo Nodularis Pipeline Drugs Molecule Types Outlook (Number of Drugs, 2024)
- Small Molecule
- Biologic
Scope
The key components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Understand the trends shaping and driving the Prurigo Nodularis market to develop business strategies.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Prurigo Nodularis market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
Which is the leading MoA for Prurigo Nodularis marketed drugs in 2024?
Receptor Antagonist MoA is the most followed MoA in 2024 in the Prurigo Nodularis marketed drugs market.
-
Which is the leading MoA for Prurigo Nodularis pipeline drugs in 2024?
Most of the drugs follow receptor antagonist MoA in 2024 in the Prurigo Nodularis drugs market.
-
Which is the leading molecule type for Prurigo Nodularis pipeline drugs in 2024?
In 2024, most of the drugs in development for Prurigo Nodularis are biologic.
-
Which are the top sponsors in the Prurigo Nodularis marketed and pipeline drugs market?
A few of the top sponsors in the Prurigo Nodularis marketed and pipeline drugs market are Incyte Corp, Sanofi, Galderma SA, Maruho Co Ltd, and Amgen Inc among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Prurigo reports




